Unicycive Therapeutics Inc (NASDAQ:UNCY) — Market Cap & Net Worth
Market Cap & Net Worth: Unicycive Therapeutics Inc (UNCY)
Unicycive Therapeutics Inc (NASDAQ:UNCY) has a market capitalization of $188.24 Million ($188.24 Million) as of June 19, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #16885 globally and #3935 in its home market, demonstrating a -3.03% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Unicycive Therapeutics Inc's stock price $7.05 by its total outstanding shares 26700027 (26.70 Million). Review UNCY current and long-term liabilities to assess the company's total debt and financial obligations.
Unicycive Therapeutics Inc Market Cap History: 2021 to 2026
Unicycive Therapeutics Inc's market capitalization history from 2021 to 2026. Data shows growth from $55.00 Million to $188.24 Million (7.21% CAGR).
Index Memberships
Unicycive Therapeutics Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.42 Trillion | 0.01% | #468 of 976 |
|
NASDAQ Composite
IXIC
|
$40.74 Trillion | 0.00% | #1665 of 3165 |
Weight: Unicycive Therapeutics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Unicycive Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Unicycive Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
34.33x
Unicycive Therapeutics Inc's market cap is 34.33 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2022 | $14.42 Million | $951.00K | -$18.06 Million | 15.16x | N/A |
| 2023 | $23.18 Million | $675.00K | -$30.54 Million | 34.33x | N/A |
Competitor Companies of UNCY by Market Capitalization
Companies near Unicycive Therapeutics Inc in the global market cap rankings as of June 19, 2026.
Key companies related to Unicycive Therapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #444 globally with a market cap of $62.63 Billion USD.
- UCB SA (BR:UCB): Ranked #549 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #573 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $458.99 |
| #444 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $62.63 Billion | $607.93 |
| #549 | UCB SA | BR:UCB | $49.68 Billion | €252.40 |
| #573 | Argen-X | BR:ARGX | $47.14 Billion | €780.20 |
Unicycive Therapeutics Inc Historical Marketcap From 2021 to 2026
Between 2021 and today, Unicycive Therapeutics Inc's market cap moved from $55.00 Million to $ 188.24 Million, with a yearly change of 7.21%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $188.24 Million | +22.18% |
| 2025 | $154.06 Million | +626.52% |
| 2024 | $21.21 Million | -8.50% |
| 2023 | $23.18 Million | +60.74% |
| 2022 | $14.42 Million | -73.79% |
| 2021 | $55.00 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 18th, 2026 the market cap of Unicycive Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $188.24 Million USD |
| MoneyControl | $188.24 Million USD |
| MarketWatch | $188.24 Million USD |
| marketcap.company | $188.24 Million USD |
| Reuters | $188.24 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Unicycive Therapeutics Inc
Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies for the treatment of kidney diseases in the United States. It develops oxylanthanum carbonate, a lanthanum-based phosphate binding agent, which is for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI-494, a nicotinamide ester deriv… Read more